October 2024 in “Journal of Neuroscience Research” In this study, researchers found that long-term treatment with 5-alpha-reductase inhibitors improved depression-like symptoms more effectively than a short-term treatment followed by withdrawal in d-galactose-induced senescent male rats, by reducing brain inflammation and oxidative stress.
7 citations
,
January 2019 in “Brazilian Journal of Pharmaceutical Sciences” This study found that Adiantum capillus-veneris extract exhibited significant antidepressant and anti-anxiety effects in rats, likely due to its antioxidant and anti-inflammatory properties.
August 2021 in “The Journal of Urology” This study found a significant association between finasteride use and reports of sexual dysfunction, particularly greater in young men using it for alopecia compared to older BPH patients.
November 2023 in “Deleted Journal” In this study, the researchers found no superiority of combining 308-nm excimer laser with intralesional corticosteroid over corticosteroid alone for treating frontal fibrosing alopecia, and reported side effects such as erythema and postinflammatory hyperpigmentation in both treatment groups.
17 citations
,
May 1998 in “Steroids” This study constructed a model to predict finasteride's inhibitory activity on 5α-reductase type 2 and calculated that a 1 μM plasma concentration, after 50 mg administration, matches prostate inhibition levels.
7 citations
,
July 1995 in “PubMed” Finasteride, a drug that changes testosterone to a different hormone, was studied and its effects over time were modeled successfully.
October 2012 in “Sax's Dangerous Properties of Industrial Materials” This trial will compare the effectiveness of spironolactone to doxycycline for treating acne in adult females, potentially offering an alternative to antibiotics and isotretinoin.
October 2004 in “European Neuropsychopharmacology” This article reviews studies on younger men using finasteride for hair loss, finding persistent sexual and nonsexual side effects like erectile dysfunction and depression, and reports lower neurosteroid levels in affected individuals.
October 2023 in “Journal of cystic fibrosis”
February 2026 in “NeuroSci” This systematic review synthesizes evidence on the distribution of 5a-reductase isozymes and their implications for mental health, finding that inhibition of neurosteroidogenesis may contribute to anxiety, depression, and suicidality, with some patients experiencing persistent psychiatric effects from finasteride or dutasteride.
August 2026 in “Asclepius International Journal of Scientific Health Science” In this systematic review, dutasteride may be more effective than finasteride for hair growth in men with androgenetic alopecia, but the comparative magnitude of this effect is highly uncertain.
April 2026 in “Frontiers in Pharmacology” This study revealed significant signals of drug-related cognitive disorders in several medications that lack relevant FDA label warnings, suggesting a need for increased clinical awareness and potential label updates.
14 citations
,
July 2016 in “Journal of Endocrinology” This study observed that equine epididymis mainly expresses the type 1 isoform of 5α-reductase and effectively converts progesterone and testosterone to DHP and DHT, while finasteride and dutasteride inhibited this activity.
2 citations
,
January 2016 in “Andrology” This case report study presents two instances of post-finasteride syndrome, highlighting the persistence of sexual adverse effects despite discontinuation of the drug, and underscores the need for increased awareness and understanding of this condition.
November 2023 in “European heart journal” In this study, finasteride improved cardiac sympathovagal balance in aging and obese male rats, also enhancing left ventricular function specifically in those modeled for aging, but not affecting healthy rats.
September 2023 in “Journal of the American Academy of Dermatology” Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
July 2026 in “Current Issues in Molecular Biology” This study found that Plerixafor, a CXCR4 antagonist, promotes melanogenesis in melanocytes by increasing MITF and tyrosinase expression and enhancing melanocyte migration, and it effectively restores pigmentation in a mouse depigmentation model without toxicity, highlighting its potential for treating pigmentary disorders.
84 citations
,
July 2008 in “Aaps Pharmscitech” Ethosomes improve finasteride delivery through skin for hair loss treatment.
50 citations
,
May 2000 in “Fertility and Sterility” This study found that flutamide was more effective than finasteride in reducing hair growth in women with hirsutism over a one-year period.
March 2024 in “The journal of sexual medicine” In this laboratory study, finasteride administration in male rats lowered dihydrotestosterone levels and reduced c-Fos protein activation in brain tissue, indicating an impact on brain regions like the hippocampus, though these effects diminished after one month of withdrawing the drug.
January 2021 in “Figshare” This study used Density Functional Theory to calculate finasteride's molecular properties, finding the GGA/PW91 method aligns well with experimental data and identifying key reactive sites for chemical interactions.
September 2018 in “Dermatologic Therapy” This article is a commentary on another piece about the clinical efficacy of oral finasteride and reports no new results.
78 citations
,
December 2008 in “The Journal of Sexual Medicine” This review highlights that sexual dysfunction associated with 5-alpha-reductase inhibitors is recognized in clinical literature, with erectile dysfunction being the most common adverse effect, followed by ejaculatory dysfunction and decreased libido.
9 citations
,
August 2021 in “Biomedicines” This study found that 17β-estradiol was the most powerful hormone for inducing APE1/Ref-1 secretion in cultured vascular endothelial cells, with secretion occurring through exosomes dependent on estrogen receptors and intracellular calcium.
This study detected insomnia risk signals associated with various medications, primarily nervous system drugs, using the FDA's Adverse Event Reporting System data from 2004 to 2024.
4 citations
,
December 1994 in “PubMed” This study found that treatment with cyproterone acetate and estradiol improved emotional well-being and acceptance of being viewed among women with hirsutism, with no significant differences between oral and transdermal estradiol groups.
January 2013 in “CINECA IRIS Institutial research information system (University of Pisa)”